Clinical trials: Decitabine, open to volunteers
Leukemia, Acute Myeloid (AML)
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
A randomized，multicenter, open-label Phase III, clinical study is conducted to evaluate the clinical benefit Clifutinib in Chinese patients with relapsed/ refractory (R/R) FLT3-mutated AML as shown with overall survival compared…
- Trial name
- NCT05586074
- Testing
- Clifutinib, LoDAC, Azacitidine
- Where
- China
- Volunteers
- 324 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
AML (Acute Myelogenous Leukemia)
Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML
Acute myeloid leukemia (AML) is a serious blood cancer that commonly affects older adults. Although patients may achieve complete remission after initial treatment, relapse remains common, especially in patients with…
- Trial name
- NCT07761702
- Testing
- Unrelated Umbilical Cord Blood Infusion, Standard consolidation chemotherapy with high-dose cytarabine
- Volunteers
- 132 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
This phase II trial evaluates the effect of azacitidine or decitabine and venetoclax in treating patients with acute myeloid leukemia that has not been treated before (treatment naive) or has come back (relapsed).
- Trial name
- NCT04905810
- Testing
- Azacitidine, Decitabine, Venetoclax
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brian Jonas
Myelofibrosis, MPN - Accelerated or Blast Phase
Oral Tetrahydrouridine-Decitabine in Patients With Advanced Myeloproliferative Neoplasms
This is a phase II, multicenter, open-label study evaluating the feasibility, safety, and efficacy of oral tetrahydrouridine-decitabine (THU-decitabine) in patients with advanced myeloproliferative neoplasms (MPN).
- Conditions
- Myelofibrosis, MPN - Accelerated or Blast Phase, Chric Phase MPN
- Trial name
- MPN-RC 127 (NCT07872709)
- Testing
- Oral THU-decitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- John Mascarenhas
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
This MyeloMATCH Master Screening and Reassessment Protocol (MSRP) evaluates the use of a screening tool and specific laboratory tests to help improve participants' ability to register to clinical trials throughout the course of…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05564390
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice
- Where
- 360 sites in United States, Canada and 1 more
- Volunteers
- 2,000 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia With Gene Mutations
Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients
The goal of this clinical trial is to learn if the combination of oral decitabine plus ivosidenib works to treat naïve adult patients with acute myeloid leukemia (AML) with IDH1 R132 mutation older than 60 years old or those who…
- Trial name
- DECISIVO (NCT07507760)
- Testing
- Decitabine/Cedazuridine 35 Mg-100 Mg ORAL TABLET, Ivosidenib Oral Tablet, Hydroxyurea
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 50 people
- Sponsor
- PETHEMA Foundation
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)
This phase II MyeloMATCH treatment substudy tests the addition of olutasidenib to usual treatment in patients with higher-risk myelodysplastic syndrome (MDS) or patients with acute myeloid leukemia (AML) with a mutation in the…
- Trial name
- NCT07153497
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Volunteers
- 132 people
- Sponsor
- National Cancer Institute (NCI)
Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial
This study aims to determine whether the recurrence rate of high-risk acute myeloid leukemia CR1 patients who received allogeneic hematopoietic stem cell transplantation with the Ruxolitinib, Decitabine combined with Bu/Cy or BuF…
- Trial name
- NCT07101588
- Testing
- Ruxolitinib, Decitabine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Chinese PLA General Hospital
High Risk Acute Lymphoblastic Leukemia
Blinatumomab Maintenance After Allo-HSCT
To evaluate the safety and efficacy of Blinatumomab maintenance after allogeneic hematopoietic stem cell transplantation for high-risk acute B-lymphoblastic leukemia.
- Trial name
- NCT06438796
- Testing
- Blinatumomab
- Volunteers
- 59 people
- Sponsor
- Ruijin Hospital
Myelodysplastic Syndromes, Acute Myeloid Leukemia
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Myeloid malignancies which include AML (acute myeloid leukemia) and MDS (myelodysplatic syndrome) are cancers of the bone marrow which lead to bone marrow failure.
- Conditions
- Myelodysplastic Syndromes, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT05184842
- Testing
- Venetoclax, Decitabine
- Where
- 3 sites in United States
- Volunteers
- 91 people
- Sponsor
- Montefiore Medical Center
Acute Myeloid Leukemia, Essential Thrombocythemia
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
This phase II trial studies how well decitabine with ruxolitinib, fedratinib, or pacritinib works before hematopoietic stem cell transplant in treating patients with accelerated/blast phase myeloproliferative neoplasms (tumors).
- Conditions
- Acute Myeloid Leukemia, Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm
- Trial name
- NCT04282187
- Testing
- Decitabine, Ruxolitinib, Fedratinib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Washington
Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell Lymphoma
A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with newly Diagnosed Diffuse Large B-cell Lymphoma
- Trial name
- NCT06683885
- Testing
- Obutinib or Decitabine, Rituximab, Compound Cyclophosphamide Tablets and Prednisone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Mingzhi Zhang
Acute Myeloid Leukemia (AML)
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
This is a multi-center, prospective, single-arm, phase 2 clinical study conducted in China to evaluate the efficacy and safety of Lisafotoclax combined with Decitabine and Homoharringtonine in patients with acute myeloid leukemia…
- Trial name
- NCT07505160
- Testing
- Lisafotoclax, Decitabine, Homoharringtonine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B Cell Lymphoma (DLBCL)
Dynamic CtDNA-guided Targeted Therapy in DLBCL
This is a prospective, single-arm, noninferiority trial involving patients with previously untreated CD20-positive DLBCL. The aim of this study is to determine the efficacy and safety of treatment stratified based on ctDNA…
- Trial name
- NCT06748521
- Testing
- R-CHOP + X
- Volunteers
- 108 people
- Sponsor
- Ruijin Hospital
DLBCL
CR-CHOP+X in Previously Untreated DEL
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL…
- Trial name
- NCT06701357
- Testing
- CR-CHOP+PD1 inhibitor, CR-CHOP + Orelabrutinib, CR-CHOP + decitabine
- Where
- China
- Volunteers
- 49 people
- Sponsor
- Ruijin Hospital
Neuroendocrine Tumors
Lutathera and ASTX727 in Neuroendocrine Tumours
Patients entered into the study will receive ASTX727 orally for 5 days, prior to receiving Lutathera treatment on Day 8, to determine whether pre-treatment with ASTX727 results in re-expression of somatostatin receptor-2 in…
- Trial name
- LANTana (NCT05178693)
- Testing
- ASTX727, Lutathera
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- Imperial College London
AML, Adult
Venetoclax-Decitabine in Untreated Elderly/Unfit AML
Acute myeloid leukemia (AML) is a highly fatal malignancy in China, with particularly poor outcomes in elderly patients. Low-intensity regimens yield low remission rates, and median overall survival (OS) typically remains under…
- Trial name
- NCT07117422
- Testing
- VEN + DEC
- Where
- China
- Volunteers
- 39 people
- Sponsor
- The Second Hospital of Hebei Medical University
PTCL, Refractory
Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL
To evaluate the safety and efficacy of Zeprumetostat-based combination therapy, selected according to genotyping results, in patients with primary refractory peripheral T-cell lymphoma (PTCL).
- Trial name
- NCT07493330
- Testing
- Zeprumetostat+Azacitadine, Zeprumetostat+Decitabine, Zeprumetostat+Chidamide
- Volunteers
- 86 people
- Sponsor
- Ruijin Hospital
Sickle Cell Disease
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).
- Trial name
- NCT04055818
- Testing
- Nicotinamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- EpiDestiny, Inc.
MDS
A Study of Oral Tetrahydrouridine-Decitabine in Relapsed or Refractory Myelodysplastic Syndromes (MDS)
The goal of this clinical trial is to learn about the safety and effectiveness of the combination drug Tetrahydrouridine (THU) and decitabine (DEC) to treat patients with relapsed or refractory myelodysplastic syndrome.
- Trial name
- NCT07006025
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Treebough Therapies